Mycospor (Bifonazole)

Bifonazole belongs to the imidazole class of antifungals. It blocks the fungal enzyme lanosterol 14α‑demethylase, which is essential for synthesising ergosterol, a key component of the fungal cell membrane. Without ergosterol, the membrane becomes unstable, leading to fungal cell death and clearance of the infection.

The dosage regimen for Mycospor is determined by the prescribing healthcare professional based on the type and severity of the infection. Typically, a thin layer is applied to the affected area once or twice daily for a period prescribed by the clinician, often ranging from one to four weeks.

Safety data for bifonazole in pregnancy and lactation are limited. It should only be used if the potential benefit outweighs any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss use with their healthcare provider.

To order Mycospor, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including any cold‑chain requirements) and assists with import documentation.

Mycospor (bifonazole) is an imidazole antifungal, similar in spectrum to clotrimazole and miconazole. Compared with some allylamine agents such as terbinafine, bifonazole may have a slightly slower onset but is effective against a broad range of dermatophytes and Candida species. Choice of therapy often depends on clinician preference, formulation availability and patient tolerance.

Mycospor should be stored at room temperature, below 25 °C, in its original packaging. Keep the container tightly closed, protect it from moisture, heat and direct sunlight. Do not freeze the product, and keep it out of reach of children.

Mycospor is applied topically to clean, dry skin. A thin film should be spread over the affected area and a small margin of surrounding healthy skin, usually once or twice daily as directed by a healthcare professional. Hands should be washed after application, and the treated area should be allowed to dry before covering.

While most reactions are mild, serious adverse events can include allergic contact dermatitis, severe skin reactions such as Stevens‑Johnson syndrome, and extensive ulceration of the treated area. If any signs of a severe reaction appear—such as swelling, blistering, fever, or widespread rash—stop use immediately and seek medical attention.

Mycospor should not be used on broken, severely inflamed or infected skin where the barrier is compromised. Individuals with known hypersensitivity to bifonazole or any other imidazole antifungal should avoid it. It is also contraindicated for use on mucous membranes, the eyes, or in patients where systemic absorption could pose a risk without medical supervision.